National AIDS Task Force Expected To Accelerate Drug Development

Bench scientists will play a major role in an ambitious effort to streamline the campaign against HIV The soon-to-be-appointed National Task Force on AIDS Drug Development may have a strong, positive impact on the research and development of antiviral therapies to counter HIV infection, say industry and academic scientists, government officials organizing the task force, and members of the AIDS-affected community. Key to the task

Written byFranklin Hoke
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share


Bench scientists will play a major role in an ambitious effort to streamline the campaign against HIV
The soon-to-be-appointed National Task Force on AIDS Drug Development may have a strong, positive impact on the research and development of antiviral therapies to counter HIV infection, say industry and academic scientists, government officials organizing the task force, and members of the AIDS-affected community. Key to the task force's effectiveness, however, will be the personnel selected by Secretary of Health and Human Services, Donna Shalala, probably in early February, to serve on it, these sources say.

"People's views run the gamut from cynical to optimistic," says activist Derek Hodel with the AIDS Action Council in Washington, D.C. "Those of us who are optimistic hope that the task force will be effective at its charter in identifying barriers to research and to drug development, of which there are many. If it's well-appointed and well- ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies